BRIM2 study was a single arm, multicenter, open-label phase II included 132 patients previously treated with V600E BRAF mutation positive advanced melanoma. Mutation status was determined by the cobas 4800 BRAF V600 mutation, a test of Roche Molecular Diagnostics companion diagnostic co-developed with RG7204. Study participants received RG7204 twice daily until disease progression. The primary endpoint of the study was evaluated by an independent review committee Orr. Secondary endpoints for the study included duration of response, progression-free survival and overall survival. Of the 132 patients who received RG7204, results showed:i) Parkin DM, Bray F, Ferlay J, P. Pisani Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55:74 – 108.
Read more: Roche reports promising phase II with the new targeted approach in advanced melanoma
